Category Archives: Cancer and neoplasms

Abstract Carcinoma of unknown primary (CUP) is a type of metastatic cancer with tissue-of-origin (TOO) unidentifiable by traditional methods. CUP patients typically have poor prognosis but therapy targeting the original cancer tissue can significantly improve patients’ prognosis. Thus, it’s critical to develop accurate computational methods to infer cancer TOO. While qPCR or microarray-based methods are […]

The Food and Drug Administration (FDA) approved Ojjaara (momelotinib) for the treatment of myelofibrosis with anemia, according to GSK, the manufacturer of the drug. “Approximately one out of every three patients have anemia at the time of their myelofibrosis diagnosis. We also know that individuals who have chronic anemia are at a much higher risk for […]

Approval is for use in myelofibrosis patients with anaemia regardless of prior myelofibrosis therapy Nearly all myelofibrosis patients are estimated to develop anaemia over the course of the disease, and over 30% will discontinue treatment due to anaemia[1],[2],[3] Ojjaara addresses key manifestations of myelofibrosis, namely anaemia, constitutional symptoms and splenomegaly GSK plc (LSE/NYSE: GSK) today […]

Feinberg investigators, students, trainees and faculty celebrated discovery and presented scientific research at Feinberg’s 17th annual Lewis Landsberg Research Day on Sept. 14. Courtesy of Nathan Mandell. Feinberg investigators, students, trainees and faculty gathered to celebrate discovery and presented scientific research posters and abstracts at Feinberg’s 17th annual Lewis Landsberg Research Day on Thursday, Sept. […]

Paolo Strati, MD, assistant professor, Department of Lymphoma and Myeloma, Division of Cancer Medicine, Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, discusses several ongoing investigations aiming to improve upon current immunotherapy combinations, highlighting the introduction of novel regimens into the treatment landscape offollicular lymphoma (FL). Clinical trials within the […]

In the open-label, multi-center phase 1/2 JACKPOT8 study, patients with relapsed/refractory PTCL received golidocitinib as an oral capsule once a day until disease progression or unacceptable AEs. A new drug application (NDA) for golidocitinib (DZD4205) as a treatment for patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) has been accepted by the National Medical Products Administration’s […]

According to a spokesperson from the NCCS, the cost of cancer treatments such as chemotherapy and radiotherapy can vary greatly, depending on the type and stage of cancer. For Ms Hoo, each chemotherapy session she attended in 2016 to treat her breast cancer cost more than S$2,000, and her mastectomy and breast reconstruction surgery cost […]

Transcript: Robert J. Motzer, MD: We’ve made a lot of progress in the treatment of kidney cancer with the advent of tyrosine kinase inhibitors, PD-1 inhibitors, and now the combination therapies. The prognosis and the outcome have changed dramatically for the better for our patients, but we still need to make better gains for our […]

Specialty